Qube Research & Technologies LTD Adverum Biotechnologies, Inc. Transaction History

Qube Research & Technologies LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.75 - $1.26 $18,187 - $30,555	-24,250 Reduced 97.13%	717 $0
Q3 2023 Nov 13, 2023	BUY	$1.5 - $2.33 $37,450 - $58,173	24,967 New	24,967 $37,000
Q3 2022 Nov 14, 2022	SELL	$0.96 - $9.68 $15,669 - $157,996	-16,322 Reduced 19.46%	67,564 $64,000
Q2 2022 Aug 15, 2022	BUY	$0.81 - $1.34 $67,947 - $112,407	83,886 New	83,886 $101,000
Q4 2021 Feb 01, 2022	SELL	$1.74 - $2.4 $41,171 - $56,788	-23,662 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$2.08 - $3.6 $49,216 - $85,183	23,662 New	23,662 $51,000
Q1 2021 May 14, 2021	SELL	$9.26 - $14.36 $105,943 - $164,292	-11,441 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$9.84 - $14.26 $193,946 - $281,064	-19,710 Reduced 63.27%	11,441 $124,000
Q3 2020 Nov 12, 2020	BUY	$10.3 - $21.64 $320,855 - $674,107	31,151 New	31,151 $321,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $681M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.